NCT00146042View on ClinicalTrials.gov

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2005

Conditions
HER-2 Positive Metastatic Breast Cancer
Interventions
DRUG

Docetaxel

DRUG

Trastuzumab

PROCEDURE

Erythromycin Breath Test (ERMBT)

Trial Locations (1)

48109

University of Michigan Cancer Center, Ann Arbor

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER